Cargando…

Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?

BACKGROUND: To evaluate surgical outcome and survival benefit after quaternary cytoreduction (QC) in epithelial ovarian cancer (EOC) relapse. METHODS: We systematically evaluated all consecutive patients undergoing QC in our institution over a 12-year period (October 2000–January 2012). All relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Fotopoulou, C, Savvatis, K, Kosian, P, Braicu, I E, Papanikolaou, G, Pietzner, K, Schmidt, S-C, Sehouli, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553531/
https://www.ncbi.nlm.nih.gov/pubmed/23321509
http://dx.doi.org/10.1038/bjc.2012.544
_version_ 1782256832015761408
author Fotopoulou, C
Savvatis, K
Kosian, P
Braicu, I E
Papanikolaou, G
Pietzner, K
Schmidt, S-C
Sehouli, J
author_facet Fotopoulou, C
Savvatis, K
Kosian, P
Braicu, I E
Papanikolaou, G
Pietzner, K
Schmidt, S-C
Sehouli, J
author_sort Fotopoulou, C
collection PubMed
description BACKGROUND: To evaluate surgical outcome and survival benefit after quaternary cytoreduction (QC) in epithelial ovarian cancer (EOC) relapse. METHODS: We systematically evaluated all consecutive patients undergoing QC in our institution over a 12-year period (October 2000–January 2012). All relevant surgical and clinical outcome parameters were systematically assessed. RESULTS: Forty-nine EOC patients (median age: 57; range: 28–76) underwent QC; in a median of 16 months (range:2–142) after previous chemotherapy. The majority of the patients had an initial FIGO stage III (67.3%), peritoneal carcinomatosis (77.6%) and no ascites (67.3%). At QC, patients presented following tumour pattern: lower abdomen 85.7% middle abdomen 79.6% and upper abdomen 42.9%. Median duration of surgery was 292 min (range: a total macroscopic tumour clearance could be achieved. Rates of major operative morbidity and 30-day mortality were 28.6% and 2%, respectively. Mean follow-up from QC was 18.41 months (95% confidence interval (CI):12.64–24.18) and mean overall survival (OS) 23.05 months (95% CI: 15.5–30.6). Mean OS for patients without vs any tumour residuals was 43 months (95% CI: 26.4–59.5) vs 13.4 months (95% CI: 7.42–19.4); P=0.001. Mean OS for patients who received postoperative chemotherapy (n=18; 36.7%) vs those who did not was 40.5 months (95% CI: 27.4–53.6) vs 12.03 months (95% CI: 5.9–18.18); P<0.001. Multivariate analysis indentified multifocal tumour dissemination to be of predictive significance for incomplete tumour resection, higher operative morbidity and lower survival, while systemic chemotherapy subsequent to QC had a protective significant impact on OS. No prognostic impact had ascites, platinum resistance, high grading and advanced age. CONCLUSION: Even in this highly advanced setting of the third EOC relapse, maximal therapeutic effort combining optimal surgery and chemotherapy appear to significantly prolong survival in a selected patients ‘group’.
format Online
Article
Text
id pubmed-3553531
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35535312014-01-15 Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Fotopoulou, C Savvatis, K Kosian, P Braicu, I E Papanikolaou, G Pietzner, K Schmidt, S-C Sehouli, J Br J Cancer Clinical Study BACKGROUND: To evaluate surgical outcome and survival benefit after quaternary cytoreduction (QC) in epithelial ovarian cancer (EOC) relapse. METHODS: We systematically evaluated all consecutive patients undergoing QC in our institution over a 12-year period (October 2000–January 2012). All relevant surgical and clinical outcome parameters were systematically assessed. RESULTS: Forty-nine EOC patients (median age: 57; range: 28–76) underwent QC; in a median of 16 months (range:2–142) after previous chemotherapy. The majority of the patients had an initial FIGO stage III (67.3%), peritoneal carcinomatosis (77.6%) and no ascites (67.3%). At QC, patients presented following tumour pattern: lower abdomen 85.7% middle abdomen 79.6% and upper abdomen 42.9%. Median duration of surgery was 292 min (range: a total macroscopic tumour clearance could be achieved. Rates of major operative morbidity and 30-day mortality were 28.6% and 2%, respectively. Mean follow-up from QC was 18.41 months (95% confidence interval (CI):12.64–24.18) and mean overall survival (OS) 23.05 months (95% CI: 15.5–30.6). Mean OS for patients without vs any tumour residuals was 43 months (95% CI: 26.4–59.5) vs 13.4 months (95% CI: 7.42–19.4); P=0.001. Mean OS for patients who received postoperative chemotherapy (n=18; 36.7%) vs those who did not was 40.5 months (95% CI: 27.4–53.6) vs 12.03 months (95% CI: 5.9–18.18); P<0.001. Multivariate analysis indentified multifocal tumour dissemination to be of predictive significance for incomplete tumour resection, higher operative morbidity and lower survival, while systemic chemotherapy subsequent to QC had a protective significant impact on OS. No prognostic impact had ascites, platinum resistance, high grading and advanced age. CONCLUSION: Even in this highly advanced setting of the third EOC relapse, maximal therapeutic effort combining optimal surgery and chemotherapy appear to significantly prolong survival in a selected patients ‘group’. Nature Publishing Group 2013-01-15 2013-01-15 /pmc/articles/PMC3553531/ /pubmed/23321509 http://dx.doi.org/10.1038/bjc.2012.544 Text en Copyright © 2013 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Fotopoulou, C
Savvatis, K
Kosian, P
Braicu, I E
Papanikolaou, G
Pietzner, K
Schmidt, S-C
Sehouli, J
Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title_full Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title_fullStr Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title_full_unstemmed Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title_short Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
title_sort quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553531/
https://www.ncbi.nlm.nih.gov/pubmed/23321509
http://dx.doi.org/10.1038/bjc.2012.544
work_keys_str_mv AT fotopoulouc quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT savvatisk quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT kosianp quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT braicuie quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT papanikolaoug quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT pietznerk quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT schmidtsc quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter
AT sehoulij quaternarycytoreductivesurgeryinovariancancerdoessurgicaleffortstillmatter